Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Equity Average (2016 - 2025)

Historic Equity Average for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to $889.4 million.

  • Ligand Pharmaceuticals' Equity Average rose 1004.25% to $889.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $889.4 million, marking a year-over-year increase of 1004.25%. This contributed to the annual value of $765.7 million for FY2024, which is 1794.16% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Equity Average of $889.4 million as of Q3 2025, which was up 1004.25% from $812.0 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Equity Average peaked at $889.4 million during Q3 2025, and registered a low of $621.9 million during Q1 2023.
  • In the last 5 years, Ligand Pharmaceuticals' Equity Average had a median value of $797.8 million in 2022 and averaged $766.4 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Equity Average crashed by 2295.34% in 2023 and then surged by 2212.2% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Equity Average (Quarter) stood at $816.6 million in 2021, then fell by 13.44% to $706.9 million in 2022, then dropped by 3.18% to $684.4 million in 2023, then increased by 22.12% to $835.8 million in 2024, then rose by 6.41% to $889.4 million in 2025.
  • Its last three reported values are $889.4 million in Q3 2025, $812.0 million for Q2 2025, and $813.0 million during Q1 2025.